Bob More brings over 20 years of life sciences investing experience to his role as a Managing Director. Previously, he was a Senior Advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” Prior to that, he was a General Partner with Frazier Healthcare Ventures and Domain Associates. Bob managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics (NASDAQ: NEOT), and Glaukos Corporation (NYSE: GLKS). Bob was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs. He was a founding board member of the Kauffman Fellows Program and serves on the boards of One Revolution and the Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.